DOCSLIB.ORG

Quali-V Extra Dry: a Novel Capsule for Delivering Hygroscopic Pharmaceutical Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quali-V Extra Dry: a Novel Capsule for Delivering Hygroscopic Pharmaceutical Drugs H&TQualicaps Presspart QUALI-V EXTRA DRY: A NOVEL CAPSULE FOR DELIVERING HYGROSCOPIC PHARMACEUTICAL DRUGS In this article, Jose Luis Encinas, Engineering & Continuous Improvement Manager, and Susana Ecenarro, Director of Scientific Business Development, both of Qualicaps Europe, explore how the use of Quali-V® Extra Dry capsules can help improve product stability and, crucially, lead to efficiencies and savings in drug product manufacture. A fundamental requirement in drug common excipients that also fit into this formulation is that the API remains stable category include PEG (low molecular under specific ICH environmental conditions weight), glycerine fatty acid esters or medium and in the finished dosage form until the end chain fatty acid triglycerides, sorbitol, of its shelf life to ensure efficacy and patient maltodextrin, citric acid, microcrystalline safety. The physical and chemical properties cellulose (MCC), polyvinylpyrrolidone of pharmaceutical solids are critically (PVP), croscarmellose sodium, sodium dependent on the presence of water/ chloride, sodium sulphate, ammonium moisture, e.g. during compaction, stability, sulphate, amines and calcium chloride. storage, and processing into formulation Inhalable powders are also extremely and final product packaging. Many APIs, sensitive to moisture, as aerosolisation as well as excipients, are moisture sensitive properties and drug delivery performance and/or hygroscopic in nature and need can be greatly impacted by the amount of to be protected as moisture can have a moisture present in the formulation. Particle Jose Luis Encinas possible negative effect on their potency aggregation due to moisture affects the Engineering & Continuous or strength, result in chemical degradation emitted dose – that is, the powder released Improvement Manager and/or polymorph forms, and could also from the capsule and device – as well as T: +34 91 663 0874 E: [email protected] potentially affect capsule characteristics. the amount of drug that reaches and is Examples of current APIs in the deposited in the lungs. market that are moisture-sensitive include The Quali-V® Extra Dry capsules pancreatin, omeprazole and lansoprazole developed by Qualicaps are specifically (proton pump inhibitors), tiotropium designed for use in administering these bromide (inhalable powder), ranitidine, moisture-sensitive or hygroscopic losartan, enalapril and dabigatran. Some formulations, both in solid oral and inhaled delivery forms, as the capsule moisture content has been reduced to 2-3.5%, from the standard HPMC capsule of 4-6%. “Particle aggregation due Susana Ecenarro Director of Scientific to moisture affects the CHARACTERISTICS OF Business Development emitted dose – that is, the QUALI-V® EXTRA DRY T: +34 91 663 0884 powder released from the E: [email protected] Quali-V® Extra Dry capsules are based capsule and device – as on Qualicaps standard Quali-V® Qualicaps Europe well as the amount of hydroxypropyl methylcellulose (HPMC) de Av del Monte Valdelatas, 4, capsules, developed to respond to the 28108 Alcobendas drug that reaches and is Madrid growing market demand for moisture- Spain 28108 deposited in the lungs.” sensitive and hygroscopic drug delivery. The primary difference is found in the www.qualicaps.com 16 www.ondrugdelivery.com Copyright © 2019 Frederick Furness Publishing Ltd Qualicaps manufacturing process. Traditional HPMC phase – but without compromising the Quali-V® Extra Dry capsules are also capsules are manufactured to obtain a final capsule’s physical or mechanical properties. equivalent in their dissolution profile to moisture content of 4-6% whereas, in order Therefore, like Quali-V®, they are made Quali-V®, which complies with the USP reduce this amount by almost half, the from plant-based ingredients, preservative dissolution test requirements of >80% production process for Quali-V® Extra Dry free, chemically inert and do not undergo dissolved API at 45 minutes (Figures 1 and 2). was adapted to incorporate an extra drying crosslinking reactions. Quali-V® Extra Dry capsules maintain their physical robustness and present minimal brittleness when exposed to ambient temperature conditions and low relative humidity (RH: 22%), despite their reduced moisture content (Figure 3). Quali-V® Extra Dry capsules preserve their moisture within the low range of 2-3.5% within ambient conditions from 15% RH to 25% RH – room conditions for low-moisture filling operations (Figure 4). An important phase of the capsule development process is testing runability for commercial production scale. As such, Qualicaps has also tested Quali-V® Extra Dry Figure 1: Dissolution profile for pH 1.2 capsule fill formulation – acetaminophen. capsules on several principal capsule high- speed filling machines – from manufacturers such as MG2, Bosch and IMA – in which they have demonstrated solid performance. BENEFITS OF QUALI-V® EXTRA DRY IN THE FILLING PROCESS The typical encapsulation process for moisture-sensitive drug products involves the feeding of the API formulation and MTS TESTER BRITTLENESS EVALUATION empty capsules separately into the filling machine in a controlled environment. API moisture content, as well as filling room CAPSULE BRITTLENESS conditions, can be set precisely by the COMPRESSION TEST (EMPTY CAPSULE; 60 PSI) manufacturer but capsule moisture will Figure 2: Dissolution profile for pH 6.8 capsule fill formulation – omeprazole pellets. be present throughout the process, during which some interaction with the API and excipients may occur. ENVIRONMENTAL CONDITIONS: 30º C/ 20% RH ENVIRONMENTALNormally the final stageCONDITIONS is drying the : 27º C/ 22% RH filled capsule – that is, moisture content is reduced from the final dosage form after the LOSS ON DRYING TEST BRITTLENESSMTS TESTER TEST LOSS ON DRYING TEST BRITTLENESS TEST BRITTLENESS EVALUATION Moisture content Broken capsules (%) filling process takes place.Moisture As removingcontent the Broken capsules (%) (mean of 5 tests) (%) (n=400 capsules) moisture from the filled(mean capsules of 5 tests may) (%)take (n=400 capsules) up to several hours (some real examples Batch E1703737 2.53 0 Batch E1703737 2.91 0 CAPSULE BRITTLENESS include 6-8 hours, as well as 12-14 hours COMPRESSION TEST (EMPTY CAPSULE; 60 PSI) Batch E1702396 2.97 0 BatchforE1702396 different drug products), the3.02 drying step 0 becomes a bottleneck in terms of timing Batch E1610425 2.58 0 within the drug manufacturing process – decreasing the overall yield. As a result, moisture removal via drying ENVIRONMENTAL CONDITIONS: 30º C/ 20% RH ENVIRONMENTAL CONDITIONS: 27º C/ 22% RH the final dosage form has two principal ® Quali-V Extra dry capsules maintain their physical robustness anddisadvantages:do not become firstly, therebrittle is whena certainexposed to ambient LOSS ON DRYING TEST BRITTLENESS TEST temperature andLOSSlow relative ON DRYINGhumidity TEST(RHBRITTLENESS: ̴ 20%). TEST timeframe in which moisture from the Moisture content Broken capsules (%) Moisture content Broken capsules (%) (mean of 5 tests) (%) (n=400 capsules) (mean of 5 tests) (%) (n=400 capsules) capsule can interact with the moisture- sensitive drug formulation and, secondly, Note: External analysis (Itene Spain) Batch E1703737 2.53 0 Batch E1703737 2.91 0 drying becomes a time-consuming part of Batch E1702396 2.97 0 Batch E1702396 3.02 0 the process with a low added value. During the runability tests previously Batch E1610425 2.58 0 Figure 3: Capsule brittleness tests. mentioned, Qualicaps simulated real Copyright © 2019 Frederick Furness Publishing Ltd www.ondrugdelivery.com 17 Quali-V® Extra dry capsules maintain their physical robustness and do not become brittle when exposed to ambient temperature and low relative humidity (RH: ̴ 20%). Note: External analysis (Itene Spain) WATERQualicaps VAPOUR ABSORPTION / DESORPTION ISOTHERM CURVE (25ºC) RH (%) wt (%) 14,94 1,9771 16,90 2,1951 18,92 2,4111 20,95 2,6282 22,96 2,8464 24,91 3,067 26,74 3,286 30,11 3,7131 36,02 4,5543 The present data are obtained by means of a volumetric method as per USP41<1241>, EP9.0 2.9.39. Figure 4: Water vapour absorption/desorption isotherm curve. Note: Internal analysis (Qualicaps® Japan) conditions of the filling process for • A temperature between 20°C and 30°C address the moisture content inherent in the moisture-sensitive drug products in order with a recommended set point of 25 ±2°C capsule shell when it comes into contact to study the behaviour and performance of • A relative humidity between 15% and with the fill – and can also negatively affect Quali-V® Extra Dry capsules. By using these 25% with a recommended set point of overall production yields. capsules (instead of traditional HPMC), the 20% ±2%. Employing Quali-V® Extra Dry capsules drying process can be avoided or at least instead of traditional HPMC capsules significantly reduced. This means potential The above requirement for handling reduces both of these potential issues – savings in total production time, as well as during the filling and packaging process is potentially improving product stability as in equipment, production staff and utilities. the only one specific to Quali-V® Extra Dry. well as leading to efficiencies and savings in The capsules also lead to the important drug product manufacture. benefit of limiting the exposure of the CONCLUSION drug formulation (moisture-sensitive or ABOUT THE COMPANY hygroscopic API and/or excipients) to the Qualicaps developed the Quali-V® Extra moisture content present in the capsule. Dry capsule
Load more

Recommended publications
  • Softgels' Clear Advantages
    DEEPDIVE REPORT March 2019 naturalproductsinsider.com Softgels’ Clear Advantages Report brought to you by DEEPDIVE REPORT Softgels’ Clear Advantages Contents Market snapshot ..................................................................................... 3 Consumer appeal .................................................................................... 4 Softgel history .......................................................................................... 6 Advantages of softgels ........................................................................... 7 How softgels are made .......................................................................... 9 Softgel challenges and solutions .......................................................11 Oxidation ...........................................................................................11 Consumer experience .......................................................................12 Dietary considerations ......................................................................12 Shelf stability ....................................................................................14 Bioavailability ....................................................................................14 Innovative developments .....................................................................16 Copyright © 2019 Informa Exhibitions LLC. All rights reserved. The publisher reserves the right to accept or reject any advertising or editorial material. Advertisers, and/or their agents, assume the
    [Show full text]
  • Oral Drug Delivery: Formulation Selection Methods & Novel Delivery Technologies
    ORAL DRUG DELIVERY: FORMULATION SELECTION METHODS & NOVEL DELIVERY TECHNOLOGIES OUTSTANDING ISSUE SPONSOR www.ondrugdelivery.com “Oral Drug Delivery: Formulation Selection Approaches CONTENTS & Novel Delivery Technologies” This edition is one in the ONdrugDelivery series of pub- No Longer a Hit-or-Miss Proposition: lications from Frederick Furness Publishing. Each issue focuses on a specific topic within the field of drug deliv- Once-Daily Formulation for Drugs with ery, and is supported by industry leaders in that field. pH-Dependent Solubility Gopi Venkatesh, Director of R&D & Anthony Recupero, EDITORIAL CALENDAR 2011: Senior Director, Business Development June: Injectable Drug Delivery (Devices Focus) Aptalis Pharmaceutical Technologies 4-8 July: Injectable Drug Delivery (Formulations Focus) September: Prefilled Syringes A possible approach for the desire to innovate October: Oral Drug Delivery Brian Wang, CEO & Dr Junsang Park, CSO November: Pulmonary & Nasal Drug Delivery (OINDP) GL PharmTech 10-13 December: Delivering Biotherapeutics SUBSCRIPTIONS: COMPANY PROFILE - To arrange your FREE subscription (pdf or print) to Mayne Pharma International 14-15 ONdrugDelivery, contact: Guy Furness, Publisher From Powder to Pill: A Rational Approach to T: +44 (0) 1273 78 24 24 E: [email protected] Formulating for First-into-Man Studies Dr Robert Harris, Director, Early Development SPONSORSHIP/ADVERTISING: Molecular Profiles Ltd 16-19 To feature your company in ONdrugDelivery, contact: Guy Furness, Publisher LiquiTime* Oral Liquid
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • A Randomized and Observer Blinded Comparison of Continuous Femoral
    a & hesi C st lin e ic n a l A f R Möller. J Anesthe Clinic Res 2011, 4:1 o e l s e a Journal of Anesthesia & Clinical DOI: 10.4172/2155-6148.1000.277 a n r r c u h o J ISSN: 2155-6148 Research Case Report Open Access A Randomized and Observer Blinded Comparison of Continuous Femoral Block and Fascia Iliaca Compartment Block in Hip Replacement Surgery Thorsten Möller1,2, Sabine Benthaus2, Maria Huber2, Ingrid Bentrup2, Markus Schofer3, Leopold Eberhart2, Hinnerk Wulf2 and Astrid Morin2* 1Department of Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany 2Department of Anesthesiology and Critical Care Medicine, Philipps-University Marburg, Marburg, Germany 3Department of Orthopedy and Rheumatology, Philipps-University Marburg, Marburg, Germany Abstract Background: Techniques, analgesic effects and functional outcome of continuous femoral nerve and fascia iliaca compartment blocks were compared in patients undergoing hip replacement surgery. Methods: 80 patients were enroled in this randomized and observer-blinded study. 40 patients received a femoral nerve catheter with a stimulating catheter (FEM group) and 40 patients a fascia iliaca compartment catheter (FIC group). Before surgery, the catheters were placed. 50 mL prilocaine 1% was administered and a continuous infusion of ropivacaine 0.2% was maintained for 24 hours. Postoperative pain management with non-steroidal anti- inflammatory agents was standardized during the first 24 hours. No bolus application of a local anesthetic was allowed during this period. Intravenous opioide PCA with piritramide (comparable with morphin) was provided for 24 hours, and the patients were instructed to titrate their pain below a level of visual analogue scale of 3.
    [Show full text]
  • Continuous Pericapsular Nerve Group Block for Postoperative Pain
    Fujino et al. JA Clinical Reports (2021) 7:22 https://doi.org/10.1186/s40981-021-00423-1 CASE REPORT Open Access Continuous pericapsular nerve group block for postoperative pain management in total hip arthroplasty: report of two cases Takashi Fujino1* , Masahiko Odo1, Hisako Okada1, Shinji Takahashi2 and Toshihiro Kikuchi1 Abstract Background: Total hip arthroplasty (THA) is one of the surgical procedures associated with severe postoperative pain. Appropriate postoperative pain management is effective for promoting early ambulation and reducing the length of hospital stay. Effects of conventional pain management strategies, such as femoral nerve block and fascia iliaca block, are inadequate in some cases. Case presentation: THA was planned for 2 patients with osteoarthritis. In addition to general anesthesia, continuous pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block were performed for postoperative pain management. Numerical rating scale (NRS) scores measured at rest and upon movement were low at 2, 12, 24, and 48 h postoperatively, suggesting that the treatments were effective for managing postoperative pain. The Bromage score at postoperative days (POD) 1 and 2 was 0. Conclusion: Continuous PENG block and LFCN block were effective for postoperative pain management in patients who underwent THA. PENG block did not cause postoperative motor blockade. Keywords: Pericapsular nerve group (PENG) block, Continuous peripheral nerve block, Total hip arthroplasty, Peripheral nerve block Background reported that it was more effective for managing postop- Total hip arthroplasty (THA) is associated with signifi- erative pain associated with THA than conventional cant postoperative pain [1]. Opioids are typically used peripheral nerve blocks [6].
    [Show full text]
  • Capsule Robot: a Theranostic Approach
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 3 Issue 10 October 2019 Review Article Capsule Robot: A Theranostic Approach Pradnya Palekar Shanbhag*, Tejal Gawade, Prerna Patil and Priyanka Deshmukh Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Affiliated to University of Mumbai, India *Corresponding Author: Pradnya Palekar Shanbhag, Head and Professor, Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada,Received: Navi September Mumbai, 11, Affiliated 2019 ; Published: to University September of Mumbai, 27, India. 2019 DOI: 10.31080/ASPS.2019.03.0407 Abstract Increasing development in healthcare systems and availability of efficient miniaturized components or systems that are economic has led to profound scope for research in many new fields. Capsule robot was one such fictional idea that turned into factual reality because of use of applicative miniaturized components. Initially capsule robots were developed for endoscopic applications. These travel inside the gastrointestinal tract and thus capture images of the gastrointestinal tract and related areas. Later, capsule robots were developed to be used as the unique tool to construct micron and sub-micron sized drug delivery systems for target delivery and treatment. This article highlights on various aspects of capsule robots in diagnosis and therapy of various disorders and diseases, togetherKeywords: called Capsule theranostic Robot; approachEndoscopy; in Diagnosis;drug delivery Therapy systems. Introduction The rising demand for non invasive methodology for diagnosis controlled manner, Drug Delivery System (DDS) capsule endoscopy was designed. There are quite a number of research studies using rine type capsules which travel inside the body were used for en Microelectromechanical Systems (MEMS) for evaluating the drug and treatment led to the invention of capsule robots.
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • A Cadaveric Study of Ultrasound-Guided Subpectineal Injectate Spread Around the Obturator Nerve and Its Hip Articular Branches
    REGIONAL ANESTHESIA AND ACUTE PAIN Regional Anesthesia & Pain Medicine: first published as 10.1097/AAP.0000000000000587 on 1 May 2017. Downloaded from ORIGINAL ARTICLE A Cadaveric Study of Ultrasound-Guided Subpectineal Injectate Spread Around the Obturator Nerve and Its Hip Articular Branches Thomas D. Nielsen, MD,* Bernhard Moriggl, MD, PhD, FIACA,† Kjeld Søballe, MD, DMSc,‡ Jens A. Kolsen-Petersen, MD, PhD,* Jens Børglum, MD, PhD,§ and Thomas Fichtner Bendtsen, MD, PhD* such high-volume blocks the most appropriate nerve blocks for Background and Objectives: The femoral and obturator nerves are preoperative analgesia in patients with hip fracture, because both assumed to account for the primary nociceptive innervation of the hip joint the femoral and obturator nerves have been found to innervate capsule. The fascia iliaca compartment block and the so-called 3-in-1-block the hip joint capsule.5 have been used in patients with hip fracture based on a presumption that local Several authors have since questioned the reliability of the anesthetic spreads to anesthetize both the femoral and the obturator nerves. FICB and the 3-in-1-block to anesthetize the obturator nerve.6–10 Evidence demonstrates that this presumption is unfounded, and knowledge Recently, a study, using magnetic resonance imaging to visualize about the analgesic effect of obturator nerve blockade in hip fracture patients the spread of the injectate, refuted any spread of local anesthetic to presurgically is thus nonexistent. The objectives of this cadaveric study were the obturator nerve after either of the 2 nerve block techniques.11 to investigate the proximal spread of the injectate resulting from the admin- Consequently, knowledge of the analgesic effect of an obturator istration of an ultrasound-guided obturator nerve block and to evaluate the nerve block in preoperative patients with hip fracture is nonexis- spread around the obturator nerve branches to the hip joint capsule.
    [Show full text]
  • Over-The-Counter Drug List
    Over-the-Counter Drug List Kentucky Single Medicaid MCO PBM Program Effective July 1, 2021 This list applies only to Kentucky Medicaid Managed Care Organizations (MCO). For Fee-for-Service refer to the OTC list on the Magellan Medicaid Administration website: https://kentucky.magellanmedicaid.com/kentucky/source/index.asp. Inclusion in this list does not guarantee coverage. Quantity, cost, and other limits may apply. Allergy, Cough, and Cold Drugs Tablets and Capsules Drug Name Strength Dosage Form All Day Allergy (cetirizine) tablet Cetirizine HCl 5 mg tablet Cetirizine HCl 10 mg tablet Chlorpheniramine maleate 4 mg tablet Chlorpheniramine maleate ER 12 mg tablet Clemastine fumarate 1.34 mg (1 mg base equiv) tablet Dextromethorphan-guaifenesin 20-400 mg tablet Dextromethorphan-guaifenesin ER 12 hr 30-600 mg tablet Dextromethorphan-guaifenesin ER 12 hr 60-1200 mg tablet Diphenhydramine HCl 25 mg capsule Diphenhydramine HCl 50 mg capsule Diphenhydramine HCl 50 mg tablet Fexofenadine HCl 60 mg tablet Fexofenadine HCl 180 mg tablet Fexofenadine-pseudoephedrine ER 12 hr 60-120 mg tablet Guaifenesin 200 mg tablet Guaifenesin 400 mg tablet Guaifenesin ER 12 hr 600 mg tablet Guaifenesin ER 12 hr 1200 mg tablet Levocetirizine dihydrochloride 5 mg tablet Loratadine 10 mg tablet Loratadine & pseudoephedrine ER 12 hr 5-120 mg tablet Loratadine & pseudoephedrine ER 24 hr 10-240 mg tablet Phenylephrine HCl 10 mg tablet Pseudoephedrine HCl 30 mg tablet Pseudoephedrine HCl ER 12 hr 120 mg tablet Pseudoephedrine-guaifenesin ER 12 hr 60-600 mg tablet Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 1 Copyright © 2021 MedImpact Healthcare Systems, Inc.
    [Show full text]
  • Applications of Polymer Blends in Drug Delivery Nasser N
    Nyamweya Future Journal of Pharmaceutical Sciences (2021) 7:18 Future Journal of https://doi.org/10.1186/s43094-020-00167-2 Pharmaceutical Sciences REVIEW Open Access Applications of polymer blends in drug delivery Nasser N. Nyamweya Abstract Background: Polymers are essential components of many drug delivery systems and biomedical products. Despite the utility of many currently available polymers, there exists a demand for materials with improved characteristics and functionality. Due to the extensive safety testing required for new excipient approval, the introduction and use of new polymers is considerably limited. The blending of currently approved polymers provides a valuable solution by which the limitations of individual polymers can be addressed. Main body: Polymer blends combine two or more polymers resulting in improved, augmented, or customized properties and functionality which can result in significant advantages in drug delivery applications. This review discusses the rationale for the use of polymer blends and blend polymer-polymer interactions. It provides examples of their use in commercially marketed products and drug delivery systems. Examples of polymer blends in amorphous solid dispersions and biodegradable systems are also discussed. A classification scheme for polymer blends based on the level of material processing and interaction is presented. Conclusion: The use of polymer blends represents a valuable and under-utilized resource in addressing a diverse range of drug delivery challenges. It is anticipated that new drug molecule development challenges such as bioavailability enhancement and the demand for enabling excipients will lead to increased applications of polymer blends in pharmaceutical products. Keywords: Polymer blends, Drug delivery, Dosage forms, Solid dispersions, Bioavailability enhancement Background that the amounts used are within the limits for which Polymers are widely used in the formulation of pharma- safety has been established.
    [Show full text]
  • Next Steps in 3D Printing of Fast Dissolving Oral Films for Commercial Production
    LJMU Research Online Ehtezazi, T, Algellay, M and Hardy, A Next steps in 3D Printing of Fast Dissolving oral Films for Commercial Production. http://researchonline.ljmu.ac.uk/id/eprint/12002/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Ehtezazi, T, Algellay, M and Hardy, A (2019) Next steps in 3D Printing of Fast Dissolving oral Films for Commercial Production. Recent Patents on Drug Delivery & Formulation. ISSN 1872-2113 LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ Next steps in 3D Printing of Fast Dissolving oral Films for Commercial Production Touraj Ehtezazi1*, Marwan Algellay1, Alison Hardy2 1School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK 2Knowledge Exchange and Commercialisation, Liverpool John Moores University, Liverpool, UK Corresponding author [email protected] 1 Abstract 3D printing technique has been utilised to develop novel and complex drug delivery systems that are almost impossible to produce by employing conventional formulation techniques.
    [Show full text]
  • Women's Hormone Replacement Therapy
    Women’s Hormone Replacement Therapy Fax To: 866-635-2329 Supervising Physician’s Name(MD/DO Only) DEA# Phone` Fax Practice Name & Address City State Zip Patient Name DOB Phone Patient Address City State Zip Bill To: • O!ce • Patient Ship To: •• O!ce Patient Estrogen* Estrogen Lotion • Estrogen Cream (hypoallergenic base) Estrogen Capsules • Bi-Est (80/20) Lotion Bi-Est (50/50) Lotion • Estradiol 0.01% & Vitamin E 200IU/gm Cream • Bi-Est (80/20) Capsule • 0.25mg/mL Lotion • 0.5mg/mL Lotion • 1mg/mL Lotion • Estriol 0.05mg & Vitamin E 200IU/gm Cream • 1.25mg Capsule • 2.5mg Capsule • 5mg Capsule • • • 2mg/mL Lotion 2.5mg/mL Lotion _______mg/mL Lotion Sig: Insert 1gm vaginally qhs for 7-14 days, then •____mg Capsule Sig: Apply _____ mL _____ time(s) topically daily, or days _____ to _____ 2-3 times weekly thereafter • • Disp: 30gm Sig: 1 Capsule PO QD or BID of cycle. Disp: _____ month supply Disp: _____ month supply Progesterone Testosterone Progesterone Lotion Progesterone Capsules Testosterone Gel • 10mg/mL Lotion • 20mg/mL Lotion • 25mg Capsule • 50mg Capsule • 100mg Capsule • 1mg/0.1mL Gel • 2mg/0.1mL Gel • 25mg/mL Lotion • _______mg/mL Lotion • 200mg Capsule •____mg Capsule • 3mg/0.1mL Gel • _______mg/0.1mL Gel Sig: Apply _____ mL _____ time(s) topically daily, or days _____ to _____ Sig: 1 Capsule PO • QD or • BID Sig: Apply 0.1mL to wrist ______ times daily. of cycle. Disp: _____ month supply Disp. ______month supply. Disp: _____ month supply Combination Therapies (PMS, Peri-Menopause, Menopause, & Cancer-Risk Patients) • Progesterone 20mg/mL Lotion • Progesterone 20mg/mL & Biest • Progesterone 10mg/mL & Biest (80/20) • IF CANCER RISK: Progesterone 20mg/mL & Sig: Apply 0.5mL BID on days 12-28 of cycle.
    [Show full text]